Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DBY42T
|
|||
| Drug Name |
LP-108
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Chronic myelomonocytic leukaemia [ICD-11: 2A40; ICD-10: C93.1] | Phase 1 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Company |
Newave Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04139434) Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug name LP-108). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.